US Justice Dept appeals ruling against embryonic stem cell research

2 September 2010

The USA's Department of Justice has appealed a district judge's ruling to ban federal funding of embryonic stem cell in the US District Court in Washington DC, declaring that it wanted Judge Royce Lamberth to lift the injunction he imposed last week (The Pharma Letters August 26 and 31).

It pointed out that the injunction was harming current federally funded human embryonic stem cell research and could force a halt to all research that is subject to government funding."Numerous ongoing projects will likely not survive even a temporary gap in funds, jeopardizing both the potential benefit of the research and the hundreds of millions of dollars of taxpayer funds already invested in it," the DoJ said in its request.

Judge Lamberth issued a temporary injunction to federal funding of embryonic stem cell on August 23, saying it involved the destruction of human embryos. The injunction was a blow to the Obama administration, which approved federal funds for expanded embryonic stem cell research on March 9, 2009. The injunction immediately halted National Institutes of Health (NIH) funding at academic and private research labs on embryonic stem cells

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology